Core Insights - Kyntra Bio reported financial results for Q4 and full year 2025, highlighting a significant decrease in revenue and an increase in net loss compared to the previous year [13][19] - The company is advancing its clinical trials, particularly the Phase 2 monotherapy trial of FG-3246 and the Phase 3 trial protocol for roxadustat, with expectations for interim results and FDA feedback in 2026 [2][5][6] Financial Performance - Total revenue for Q4 2025 was $1.3 million, down from $3.1 million in Q4 2024 [13] - Full year 2025 revenue totaled $6.4 million, a decrease from $29.6 million in 2024 [13] - Net loss for Q4 2025 was $14.6 million, or $3.61 per share, compared to a net loss of $8.7 million, or $2.15 per share, in Q4 2024 [13][19] - For the full year 2025, net loss was $58.2 million, or $14.40 per share, compared to a net loss of $153.1 million, or $38.26 per share, in 2024 [13][19] - As of December 31, 2025, the company had $109.4 million in cash and equivalents, sufficient to fund operations into 2028 [13] Clinical Developments - The Phase 2 monotherapy trial of FG-3246 is actively enrolling, with interim analysis expected in the second half of 2026 [5][6] - Positive results from a combination study of FG-3246 with enzalutamide were presented at ASCO GU 2026, showing a median radiographic progression-free survival of 7.0 months [6] - The pivotal Phase 3 trial protocol for roxadustat has been submitted to the FDA for treating anemia in patients with lower-risk myelodysplastic syndromes [5][6] Upcoming Milestones - Kyntra Bio anticipates feedback from the FDA regarding the Phase 3 trial protocol for roxadustat shortly, with plans to initiate the trial in the second half of 2026 [2][5] - The company is exploring opportunities to develop roxadustat either internally or with a strategic partner [6]